Media stories about Amicus Therapeutics (NASDAQ:FOLD) have been trending somewhat positive on Wednesday, according to Accern Sentiment. The research firm identifies negative and positive news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Amicus Therapeutics earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.0633802820057 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the news articles that may have effected Accern Sentiment’s rankings:
- Trending Stocks Analysis Report: Amicus Therapeutics, Inc. (NASDAQ:FOLD), Iridium Communications Inc. (NASDAQ … – The Oracle Examiner (oracleexaminer.com)
- Are you searching Analysts Rated Stock: Amicus Therapeutics, Inc. (FOLD) – Wall Street Morning (wallstreetmorning.com)
- Zacks Investment Research Downgrades Amicus Therapeutics (FOLD) to Sell (americanbankingnews.com)
- Amicus Therapeutics, Inc. (FOLD) SVP Sells $131,250.00 in Stock (americanbankingnews.com)
- One Stock for High Risk Investors: Amicus Therapeutics, Inc. (FOLD) – Wallstreet Investorplace (wallstreetinvestorplace.com)
Amicus Therapeutics (NASDAQ FOLD) traded down $0.12 during trading hours on Wednesday, hitting $15.04. The company had a trading volume of 549,965 shares, compared to its average volume of 3,457,316. The company has a debt-to-equity ratio of 0.47, a quick ratio of 5.53 and a current ratio of 5.60. Amicus Therapeutics has a fifty-two week low of $6.41 and a fifty-two week high of $17.40. The firm has a market capitalization of $2,810.85, a PE ratio of -8.30 and a beta of 1.60.
A number of research firms have recently commented on FOLD. BidaskClub downgraded Amicus Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, December 7th. Zacks Investment Research downgraded Amicus Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, December 19th. Cowen restated a “buy” rating and set a $22.00 price target on shares of Amicus Therapeutics in a research note on Wednesday, January 10th. ValuEngine upgraded Amicus Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, Robert W. Baird set a $20.00 price objective on Amicus Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, February 7th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company. Amicus Therapeutics currently has an average rating of “Buy” and an average target price of $19.06.
In related news, insider Jay Barth sold 20,000 shares of the stock in a transaction that occurred on Tuesday, January 23rd. The stock was sold at an average price of $16.80, for a total value of $336,000.00. Following the completion of the transaction, the insider now directly owns 105,409 shares of the company’s stock, valued at approximately $1,770,871.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO John F. Crowley sold 65,581 shares of the stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $13.51, for a total value of $885,999.31. Following the completion of the transaction, the chief executive officer now directly owns 393,076 shares of the company’s stock, valued at $5,310,456.76. The disclosure for this sale can be found here. Insiders have sold 207,870 shares of company stock valued at $3,066,112 over the last ninety days. Corporate insiders own 3.40% of the company’s stock.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.